MaxCyte Inc logo

MXCT - MaxCyte Inc News Story

886p -14.0  -1.6%

Last Trade - 07/05/21

Sector
Healthcare
Size
Mid Cap
Market Cap £762.2m
Enterprise Value £740.7m
Revenue £18.8m
Position in Universe 499th / 1819

RCS - MaxCyte, Inc. - Participation in Upcoming Investor Conferences

Tue 23rd February, 2021 7:00am
RNS Number : 9618P
MaxCyte, Inc.
22 February 2021
 

 

 

                           

FOR IMMEDIATE RELEASE

 

MaxCyte to Participate in Two Upcoming Virtual Healthcare Investor Conferences

 

GAITHERSBURG, MD, February 23, 2021 - MaxCyte, Inc., a global cell-based therapies and life sciences company, today announced two upcoming presentations at virtual healthcare investor conferences. Details are as follows:

 

Cowen 41st Annual Health Care Conference

Who: Doug Doerfler, President & Chief Executive Officer, and Amanda Murphy, Chief Financial Officer, will present a corporate overview

Dates: Virtual conference March 1 - 4, 2021

MaxCyte Presentation Details: March 1, 1:20 - 1:50 p.m. ET

An archived version of the presentation will be made available following the conference in the Investors section of the Company website

 

H.C. Wainwright & Co Global Life Sciences Conference

Who: Doug Doerfler, President & Chief Executive Officer, will present a corporate overview

Dates: Virtual conference March 9 - 10, 2021

MaxCyte Presentation Details: Available on demand to conference participants March 9 - 10, 2021

 

About MaxCyte

MaxCyte is a world-leading provider of cell-engineering platform technology and is responsible for helping to bring next‐generation cell and gene-editing therapies to life. The Company's technology is deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licenses have been granted for more than 140 cell therapy programs, with more than 100 licensed for clinical use, and the Company has now entered into 12 clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998 and is headquartered in Gaithersburg, Maryland, US. For more information, visit www.maxcyte.com.

 

 

For further information, please contact:

 

MaxCyte Inc.

Doug Doerfler, Chief Executive Officer

Amanda Murphy, Chief Financial Officer

 

 

+1 301-944-1660

 

 


Nominated Adviser and Joint Corporate Broker

Panmure Gordon

Emma Earl / Freddy Crossley

Corporate Broking

Rupert Dearden

 

 

+44 (0)20 7886 2500

 

Joint Corporate Brokers

Numis Securities Limited

James Black / Duncan Monteith / Matthew O'Dowd

 

 

 

+44 (0)20 7260 1000

 

Stifel Nicolaus Europe Limited

Healthcare Investment Banking

Nicholas Moore / Ben Maddison / Samira Essebiyea

Corporate Broking

Nick Adams

 

 

+44 (0) 20 7710 7600

 

Financial PR Adviser

Consilium Strategic Communications

Mary-Jane Elliott / Chris Welsh

 

+44 (0)203 709 5700

maxcyte@consilium-comms.com

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAEAEAAAALFEAA
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.